8-K 1 v158454_8k.htm Unassociated Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
__________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 

Date of Report (Date of earliest event reported):                August 12, 2009
 
IMMUCOR, INC.
(Exact name of registrant as specified in its charter)


Georgia
0-14820
22-2408354
(State or other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)

3130 Gateway Drive, Norcross, Georgia
  
30071
(Address of principal executive offices)
  
(Zip Code)

Registrant's telephone number, including area code: (770) 441-2051

Not Applicable
(Former name or former address,
if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Item 5.02.                                Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
Executive Officer Salary Increases.  On August 12, 2009, the Compensation Committee of the Board of Directors increased the annual base compensation for the following executive officers of the Company to the amounts indicated, effective as of June 1, 2009:

Ralph A. Eatz
Senior VP, Chief Scientific Officer
$428,000
Richard A. Flynt
Chief Financial Officer
$340,000
Philip H. Moïse
VP and General Counsel
$488,000
 
The Compensation Committee also approved an increase in the base compensation of Dr. Gioacchino De Chirico, the Company’s President and CEO. However, Dr. De Chirico declined the increase.
 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
IMMUCOR, INC.
 
 
 
 
 
Date:  August 18, 2009
By:
/s/ Philip H. Moïse
   
Philip H. Moïse
   
Vice President and General Counsel